Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $8.3 million.

  • Lifecore Biomedical's Cash & Current Investments fell 2.33% to $8.3 million in Q2 2025 from the same period last year, while for May 2025 it was $31.6 million, marking a year-over-year decrease of 13.29%. This contributed to the annual value of $8.3 million for FY2025, which is 2.33% down from last year.
  • As of FY2025, Lifecore Biomedical's Cash & Current Investments stood at $8.3 million, which was down 2.33% from $8.5 million recorded in FY2024.
  • Lifecore Biomedical's Cash & Current Investments' 5-year high stood at $19.1 million during FY2023, with a 5-year trough of $763,000 in FY2021.
  • Its 3-year average for Cash & Current Investments is $11.9 million, with a median of $8.5 million in 2024.
  • As far as peak fluctuations go, Lifecore Biomedical's Cash & Current Investments surged by 1,826.44% in 2023, and later plummeted by 55.68% in 2024.
  • Yearly analysis of 5 years shows Lifecore Biomedical's Cash & Current Investments stood at $763,000 in 2021, then grew by 29.88% to $991,000 in 2022, then spiked by 1,826.44% to $19.1 million in 2023, then tumbled by 55.68% to $8.5 million in 2024, then decreased by 2.33% to $8.3 million in 2025.